Join our experts
The discussion will focus on practical approaches and considerations when selecting endpoints aligned to specific cardiometabolic comorbidities, involving relevant patient populations earlier in development, and integrating advanced metabolic, biomarker, and functional assessments from pre-clinical planning through Phase 1-2 study designs.
Register now to secure your place and be part of the discussion shaping the future of cardiometabolic trials.
